This article was originally published on 17 January 2013 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. Market conditions, pipeline statuses and regulatory positions described reflect the state of knowledge at that date.
A historic approval
On 17 January 2013, Protein Sciences Corporation announced that the US FDA had approved its recombinant influenza vaccine FluBlok for individuals aged 18-49 years - the first recombinant vaccine for human influenza approved in the United States. FluBlok joins nine other influenza vaccines competing for an estimated 145 million doses during the 2012-13 US influenza season.
FluBlok is manufactured using Protein Sciences' proprietary baculovirus expression vector system (BEVS) and expresSF+® cell line, which does not use live virus. This allows the vaccine to be manufactured in approximately two months - significantly faster than classical egg-based production - an important consideration for pandemic preparedness. The vaccine contains three times the standard hemagglutinin (HA) content (135μg per dose) and demonstrated approximately 44.6% efficacy against all circulating influenza strains in its Phase III US study (n=~4,600).
FluBlok contains 3x the standard HA content (45μg vs the standard 15μg), contributing to its differentiated profile
A long road to approval
FluBlok's approval was a long time coming. Clinical studies began as far back as 1993. A formal IND was not submitted until 2004, FDA Fast Track designation was granted in 2006, and a BLA was submitted in April 2008 requesting accelerated approval. A complete response letter in 2008 requesting additional efficacy data delayed proceedings further. An attempted acquisition by Emergent BioSolutions in 2009 also fell through. The final signal of impending success was Protein Sciences' December 2012 acquisition of the former Pearl River, Wyeth plant to facilitate production scale-up.
Commercial challenges ahead
Despite the milestone approval, substantial commercial hurdles remain. FluBlok's development has been almost exclusively US-based, with only a Japanese Phase III study (ASP7374, with UMN/Astellas) in progress internationally. The paediatric market, dominated by Sanofi's Fluzone, remains inaccessible. The transition to quadrivalent (QIV) format - a market requirement that major players were already executing - represents another gap. And many potential product differentiators (egg-free, preservative-free, higher HA content) have already been partially addressed by competitors occupying niche positions.
"To fully leverage FluBlok's cost advantages requires economies of scale and big volumes - which in turn requires a powerful global marketing partner willing to invest in demand creation."
FluBlok was planned to be available in limited supply for the 2012-13 season and more widely for 2013-14. With approximately 500,000 doses planned for 2014-15, a significant commercial scale-up is needed before Protein Sciences can meaningfully challenge the established order.